Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

CD86 (B7-2) Monoclonal Antibody (GL1), PerCP-eFluor™ 710, eBioscience™, Invitrogen™

Rat Monoclonal Antibody

Supplier:  Invitrogen 46086282

Encompass_Preferred

 View more versions of this product

Catalog No. 46-086-282


Edge
Explore available promotions
Add to Cart

Description

Description

The GL1 MAb reacts with mouse CD86, an ∽80 kDa surface receptor also known as B7-2. CD86 and CD80 are members of the B7 family of costimulatory molecules. CD86 is expressed at low level on B cells, macrophages, and dendritic cells and is upregulated on B cells through a variety of surface stimuli including the BCR complex, CD40 and some cytokine receptors. CD86 is also expressed by activated mouse T cells and thioglycolate-elicited peritoneal cells. In addition to CD80 (B7-1), CD86 is a counter-receptor for the T cell surface molecules CD28 and CD152 (CTLA-4). This interaction plays a critical role in T-B crosstalk, T cell costimulation, autoantibody production and Th2-mediated Ig production. The kinetics of upregulation of CD86 upon stimulation, supports its major contribution during the primary phase of an immune response.

CD86 is one of two ligands (the other CD80) for CTLA4 and CD28. CD86 acts as costimulatory molecule in eliciting T-cell help during antigen presentation. Antigen presentation in the absence of sufficient co-stimulation involving CD86/CD80 can induce tolerance. CD80 appears to play a role distinct from CD80 in T helper cell differentiation. CD86 is a type I membrane protein that is a member of the immunoglobulin superfamily. The CD86 protein is expressed by antigen-presenting cells, and it is the ligand for two proteins at the cell surface of T cells, CD28 antigen and cytotoxic T-lymphocyte-associated protein 4. Binding of CD86 with CD28 antigen is a costimulatory signal for activation of the T-cell. Binding of CD86 with cytotoxic T-lymphocyte-associated protein 4 negatively regulates T-cell activation and diminishes the immune response. Alternative splicing results in two transcript variants encoding different isoforms of CD86. Additional transcript variants have been described for CD86, but their full-length sequences have not been determined. Diseases associated with CD86 dysfunction include gallbladder squamous cell carcinoma and myocarditis.
TRUSTED_SUSTAINABILITY
Specifications

Specifications

CD86 (B7-2)
Monoclonal
0.2 mg/mL
PBS with 0.09% sodium azide; pH 7.2
P42082
CD86
Affinity chromatography
RUO
12524
4° C, store in dark, DO NOT FREEZE!
Liquid
Flow Cytometry
GL1
PerCP-eFluor 710
CD86
activation B7-2 antigen; B lymphocyte activation antigen B72; B7; B7.2; B70; B7-2; B-lymphocyte activation antigen B7-2; BU63; CD28 antigen ligand 2; Cd28l2; CD28LG2; CD86; CD86 antigen; CD86 antigen (CD28 antigen ligand 2, B7-2 antigen); CD86 antigen precursor; CD86 molecule; CLS1; CTLA-4 counter-receptor B7.2; early T cell costimulatory molecule-1; early T-cell costimulatory molecule 1; Early T-cell co-stimulatory molecule 1; ETC-1; FUN-1; LAB72; Ly58; Ly-58; MB7; MB7-2; membrane glycoprotein; MGC34413; T-lymphocyte activation antigen CD86; TS/A-2
Rat
100 μg
Primary
Mouse
Antibody
IgG2a κ
Product Suggestions

Product Suggestions

Videos
SDS
Documents

Documents

Product Certifications
Promotions

Promotions

Product Content Correction

The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.